We are live on ! Find out more
SCM

Soleus Capital Management Portfolio holdings

AUM $2.47B
1-Year Est. Return 115.63%
This Fund
S&P 500
This Quarter Est. Return
+2.63%
1 Year Est. Return
+115.63%
3 Year Est. Return
+435.52%
5 Year Est. Return
+604.31%
10 Year Est. Return
–
AUM
$2.47B
AUM Growth
-$242M
Cap. Flow
-$190M
Cap. Flow %
-7.68%
Top 10 Hldgs %
50.34%
Holding
119
New
24
Increased
30
Reduced
30
Closed
26

Top Buys

Rank Stock Value
1
PODD icon
Insulet
PODD
+$104M
2
VCEL icon
Vericel Corp
VCEL
+$63.4M
3
UTHR icon
United Therapeutics
UTHR
+$63.3M
4
KRYS icon
Krystal Biotech
KRYS
+$56.4M
5
PGNY icon
Progyny
PGNY
+$44.3M

Top Sells

Rank Stock Value
1
DXCM icon
DexCom
DXCM
+$80.6M
2
FOLD
Amicus Therapeutics
FOLD
+$74.2M
3
CELC icon
Celcuity
CELC
+$57.1M
4
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$39M
5
GSK icon
GSK
GSK
+$31.3M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
DYN icon
101
Dyne Therapeutics
DYN
$3.94B
– –
-10,000
Closed -$196K
ERAS icon
102
Erasca
ERAS
$6.53B
– –
-2,162,162
Closed -$8.04M
FOLD
103
DELISTED
Amicus Therapeutics
FOLD
– –
-5,207,284
Closed -$74.2M
GSK icon
104
GSK
GSK
$102B
– –
-639,000
Closed -$31.3M
KOD icon
105
Kodiak Sciences
KOD
$2.56B
– –
-60,000
Closed -$1.68M
MDGL icon
106
Madrigal Pharmaceuticals
MDGL
$12.6B
– –
-500
Closed -$291K
MLTX icon
107
MoonLake Immunotherapeutics
MLTX
$1.59B
– –
-400,000
Closed -$5.27M
NBIX icon
108
Neurocrine Biosciences
NBIX
$17.4B
– –
-175,982
Closed -$25M
OLMA icon
109
Olema Pharmaceuticals
OLMA
$1.01B
– –
-69,874
Closed -$1.75M
QDEL icon
110
QuidelOrtho
QDEL
$1.13B
– –
-75,000
Closed -$2.14M
RAPT
111
DELISTED
RAPT Therapeutics
RAPT
– –
-764,000
Closed -$25.9M
TERN
112
DELISTED
Terns Pharmaceuticals
TERN
– –
-212,710
Closed -$8.59M
TFX icon
113
Teleflex
TFX
$5.93B
– –
-190,000
Closed -$23.2M
THC icon
114
Tenet Healthcare
THC
$16.7B
– –
-92,500
Closed -$18.4M
VKTX icon
115
Viking Therapeutics
VKTX
$4.41B
– –
-70,000
Closed -$2.46M
XBI icon
116
PUT
State Street SPDR S&P Biotech ETF
XBI
$10.4B
– –
-2,900,000
Closed -$354M
GUTS icon
117
Fractyl Health
GUTS
$122M
– –
-400,000
Closed -$880K
GRAL
118
GRAIL Inc
GRAL
$2.96B
– –
-11,000
Closed -$941K
BCAX
119
Bicara Therapeutics
BCAX
$1.78B
– –
-100,000
Closed -$1.68M
1 2 3 4
5

Similar funds

TW
Trajan Wealth Scottsdale, Arizona $2.48B AUM 17.44% 1-Year Est. Return
JC
JB Capital Wethersfield, Connecticut $2.48B AUM 22.31% 1-Year Est. Return
M
Mirova Paris, France $2.46B AUM 11.42% 1-Year Est. Return
SG
Sourcerock Group Denver, Colorado $2.48B AUM 72.25% 1-Year Est. Return
BW
BIP Wealth Atlanta, Georgia $2.46B AUM 14.38% 1-Year Est. Return
BL
Balentine LLC Atlanta, Georgia $2.48B AUM 17.44% 1-Year Est. Return
FFA
First Foundation Advisors Irvine, California $2.48B AUM 18.56% 1-Year Est. Return
GWM
Greenwich Wealth Management Greenwich, Connecticut $2.45B AUM 39.53% 1-Year Est. Return

Soleus Capital Management's Q1 2026 Portfolio in Review

As of Q1 2026, Soleus Capital Management held 119 positions worth $2.47B, down 8.9% from $2.71B the previous quarter. Its ten largest holdings account for 50% of the portfolio.

Soleus Capital Management withdrew a net $190M in Q1 2026, closing 26 positions and reducing 30 holdings. Its most notable exit was Amicus Therapeutics, an estimated $74.2M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 87% a quarter earlier.

Against the trend, Soleus Capital Management opened a new position in Progyny worth $35.1M.

  • Soleus Capital Management's largest Q1 2026 buy was Progyny: 2,067,000 shares worth $35.1M.
  • Soleus Capital Management added most to Insulet in Q1 2026, an estimated $104M increase.
  • Soleus Capital Management's biggest Q1 2026 reduction was DexCom, cutting an estimated $80.6M.
  • Soleus Capital Management fully exited Amicus Therapeutics in Q1 2026, selling an estimated $74.2M.
  • Soleus Capital Management's ten largest holdings make up 50% of its $2.47B portfolio in Q1 2026.
  • Soleus Capital Management opened 24 new positions and closed 26 in Q1 2026.
  • Soleus Capital Management's portfolio value fell 8.9% quarter-over-quarter to $2.47B.

Based on Soleus Capital Management's 13F filing for Q1 2026, filed 14 May 2026.